Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 17/20 | 0.57 |
| ▸ | HTR1A | P08908 | 8/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD5 | P21918 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30363927 | 0.88 | HTR7 (0.62) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL19691138 | 0.88 | HTR7 (0.62) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL5999408 | 0.86 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL9689277 | 0.84 | HTR2A (0.62) | DRD2DRD3DRD4HTR2A | |
| SCHEMBL1232169 | 0.82 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL3227442 | 0.82 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL318502 | 0.82 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL8240109 | 0.82 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL6696116 | 0.82 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL29612136 | 0.82 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165859-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-3625224-B1 | N-SUBSTITUTED INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3625224-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20200069686-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-05 | — | — | US | disclosed |
| CN-110621666-A | N-substituted indole derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018210995-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| EP-1706113-B1 | A PROCESS FOR THE PREPARATION OF 4-(2-DIPROPYLAMINOETHYL)-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE | USV LTD (IN) | 2008-12-10 | — | — | EP | disclosed |
| US-7378439-B2 | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride | USV, LTD. (IN) | 2008-05-27 | — | — | US | disclosed |
| CN-1909901-A | A process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride | USV LTD (IN) | 2007-02-07 | — | — | CN | disclosed |
| EP-1706113-A1 | A PROCESS FOR THE PREPARATION OF 4-(2-DIPROPYLAMINOETHYL)-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE | USV Limited (IN) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005067922-A1 | A PROCESS FOR THE PREPARATION OF 4-(2-DIPROPYLAMINOETHYL)-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE | USV LIMITED (IN) | 2005-07-28 | — | — | WO | disclosed |
| US-20050159605-A1 | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride | USV LIMITED (IN) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165859-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | PTGER2, PTGER1, PTGDR2 | HTR7 83/4885HTR1A 37/4885DRD2 117/4885 |
| US-20050159605-A1 | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride | PARK7, SNCA, TPH1 | HTR7 78/4885HTR1A 14/4885DRD2 18/4885 |
| US-20200069686-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | PTGER2, PTGER1, PTGDR2 | HTR7 83/4885HTR1A 37/4885DRD2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.